On April 8, 2024, Jinling Pharmaceutical Company Limited closed the transaction. The company issued 117,924,528 A shares at a price of CNY 6.36 per share for gross proceeds of CNY 749,999,998.08. The company incurred issue expenses of CNY 7,367,708.75 in the transaction.

The transaction included participation from new investors Nanjing New Industrial Investment Group Co.,Ltd. for 31,446,541 shares for gross proceeds of CNY 200,000,000.76, Nuode Asset Management Co., Ltd. for 20,573,899 shares for gross proceeds of CNY 130,849,997.64, Jiangsu State-owned Enterprise Mixed Ownership Reform Fund (L.P.), a fund managed by Jiangsu High-Tech Investment Group Co., Ltd. for 15,723,270 shares for gross proceeds of CNY 99,999,997.20, Nanjing Kecheng Software Technology Co., Ltd. for 11,006,289 shares for gross proceeds of CNY 69,999,998.04, Caitong Fund Management Co., Ltd. for 9,748,427 shares for gross proceeds of CNY 61,999,995.72, Shanghai Guotai Junan Securities Asset Management Co., Ltd. for 8,647,798 shares for gross proceeds of CNY 54,999,995.28, Guotai Junan Securities Co., Ltd. for 8,490,566 shares for gross proceeds of CNY 53,999,999.76, Valin Jinshan (Tianjin) Industry Investment Fund Partnership Ent. (L.P.), a fund managed by Valin Jinshan Industrial Investment Management Co., Ltd. and Hunan Dice Runtong Private Equity Fund Management Co., Ltd. for 6,289,308 shares for gross proceeds of CNY 39,999,998.88, Guangdong Tongmao Fumin Investment Management Partnership Enterprise (Limited Partnership) for 3,930,817 shares for gross proceeds of CNY 24,999,996.12, Huatai Asset Management Co., Ltd. for 2,067,613 shares for gross proceeds of CNY 13,150,018.68.